What trends in EYPT's EPS suggest for 2025 investments?

**EyePoint Pharmaceuticals (EYPT) faces significant challenges in 2025**, as indicated by its EPS trends, which suggest that investors should approach with caution.

1. **Recent Performance**: EYPT's most recent EPS was a significant loss of $1.16 for Q4 2024, missing the analyst estimate by $0.54. This indicates a substantial shortfall in earnings, which could be a red flag for investors looking for profitability.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|EYPT|EYPT.O|EyePoint|2024 Q1|1.785714285714287|-0.55|185|
|EYPT|EYPT.O|EyePoint|2024 Q2|4.9180327868852505|-0.58|185|
|EYPT|EYPT.O|EyePoint|2024 Q3|-63.63636363636363|-0.54|185|

2. **Trend Analysis**: The EPS has shown a substantial decline of 27.47% from the previous quarter, suggesting a worsening financial performance. This trend is concerning for investors who expect improvements or at least stability in their investments.

|code|Ticker|Name|Date|Diluted EPS (FY) YoY|Diluted EPS (FY)|market_code|
|---|---|---|---|---|---|---|
|EYPT|EYPT.O|EyePoint|2020|34.9264705882353|-3.54|185|
|EYPT|EYPT.O|EyePoint|2021|42.65536723163842|-2.03|185|
|EYPT|EYPT.O|EyePoint|2022|-34.9753694581281|-2.74|185|
|EYPT|EYPT.O|EyePoint|2023|33.57664233576643|-1.82|185|
|EYPT|EYPT.O|EyePoint|2024|-27.472527472527457|-2.32|185|

3. **Analyst Expectations**: The average analyst price target is $29.33, with a consensus rating of "Strong Buy". This suggests that analysts are optimistic about the company's future, potentially driven by factors not immediately apparent from the EPS trends.

4. **Historical Context**: EYPT has a history of missing EPS estimates, with previous quarters showing similar trends. This track record could be indicative of underlying issues within the company that are not yet resolving.
5. **Cash Flow and Stability**: The company's cash flow has been negative in recent periods, with free cash flow and operating cash flow being significant outflows. This could raise concerns about the company's ability to sustain operations and invest in growth.
6. **Investment Consideration**: Given the current EPS trends and the absence of positive earnings surprises, investors should exercise caution. While the analyst consensus is positive, the recent performance and trend data suggest that 2025 could be a challenging year for EYPT investors, potentially requiring a more patient or speculative investment approach.

In conclusion, while there is optimism among analysts, the EPS trends and historical performance of EYPT suggest that potential investors should carefully consider the risks and possibly await signs of improvement or a turnaround before committing to investments in 2025.